| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b012ccfd2fa9e27c506c64cb338e0af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37b36726b8c2d3a2fe627ab8caf1e052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03c4720e107878f494e6eb5a8e8500ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70539 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4747d3fdf94479517c3bdc9b2c2a2278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e30d496f729bde3b95685ffe16c34d2b |
| publicationDate |
2019-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019048503-A1 |
| titleOfInvention |
METHOD FOR PREDICTING THE RISK OF GRAFT REJECTION |
| abstract |
The present invention relates to an in vitro method for determining the risk of graft rejection in a grafted subject. The inventors have demonstrated that NK immune effector cells inborn could trigger microvascular inflammation and chronic transplant rejection. NK-mediated rejection was due to the lack of expression, by the graft, of at least one type of HLA-I ligand for a KIR inhibitor expressed by the recipient NK cells. Thus, the invention relates to an in vitro method for predicting the risk of graft rejection in a grafted subject, comprising detecting the "missing-self" activation of NK cells. The inventors have also demonstrated that mTOR inhibitors are effective in preventing rejection of a "missing-self" transplant. The invention thus relates to a mTor inhibitor for use in the prevention or treatment of a graft recipient subject with a risk of rejection of a "missing-self" graft. |
| priorityDate |
2017-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |